Gary K. Lee - Nov 16, 2023 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Signature
/s/ Hector Casab, as Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Nov 16, 2023
Transactions value $
$0
Form type
4
Date filed
11/20/2023, 08:54 PM
Previous filing
Feb 28, 2023
Next filing
Feb 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LYEL Common Stock 12.7K Nov 16, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Stock Option (right to buy) Award +800K 800K Nov 16, 2023 Common Stock 800K $1.87 Direct F2, F3, F4
transaction LYEL Stock Option (right to buy) Disposed to Issuer -800K -100% 0 Nov 16, 2023 Common Stock 800K $6.04 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,702 shares acquired on November 18, 2022, 6,205 shares acquired on May 18, 2023 and 1,793 shares acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan.
F2 350,000 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following thirty-nine months based on the original vesting commencement date.
F3 The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date.
F4 Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options.
F5 1/4 of the option shares vested on January 31, 2023, with the remaining option shares vesting in equal monthly installments over the following thirty-six months.